Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZB-06 is a first-in-class, non-hormonal, on-demand contraceptive vaginal film. It contains 20 mg of HC4-N, a human contraceptive monoclonal antibody, embedded in a polyvinyl alcohol-based film for topical intravaginal administration. Developed through a collaboration between ZabBio, Boston University, Mucommune, and Kentucky BioProcessing, ZB-06 aims to provide contraceptive efficacy by acting as an anti-sperm agent. The project is funded by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and The Bill & Melinda Gates Foundation. Kentucky BioProcessing manufactures the active antibody ingredient using its plant-based platform. The long-term goal for ZB-06 is to develop a multi-purpose prevention technology with both contraceptive and antiviral activities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZB-06.